Muutke küpsiste eelistusi

Intellectual Property Law and Access to Medicines: TRIPS Agreement, Health, and Pharmaceuticals [Kõva köide]

Edited by , Edited by
  • Formaat: Hardback, 504 pages, kõrgus x laius: 234x156 mm, kaal: 857 g, 7 Tables, black and white; 11 Line drawings, black and white; 11 Illustrations, black and white
  • Sari: Law, Development and Globalization
  • Ilmumisaeg: 29-Jul-2021
  • Kirjastus: Routledge
  • ISBN-10: 0367436388
  • ISBN-13: 9780367436384
  • Formaat: Hardback, 504 pages, kõrgus x laius: 234x156 mm, kaal: 857 g, 7 Tables, black and white; 11 Line drawings, black and white; 11 Illustrations, black and white
  • Sari: Law, Development and Globalization
  • Ilmumisaeg: 29-Jul-2021
  • Kirjastus: Routledge
  • ISBN-10: 0367436388
  • ISBN-13: 9780367436384
The history of patent harmonization is a story of dynamic actors, whose interactions with established structures shaped the patent regime. From the inception of the trade regime to include intellectual property (IP) rights to the present, this book documents the role of different sets of actors states, transnational business corporations, or civil society groups and their influence on the structures such as national and international agreements, organizations, and private entities that have caused changes to healthcare and access to medication. Presenting the debates over patents, trade, and the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement), as it galvanized non-state and nonbusiness actors, the book highlights how an alternative framing and understanding of pharmaceutical patent rights emerged: as a public issue, instead of a trade or IP issue. The book thus offers an important analysis of the legal and political dynamics through which the contest for access to lifesaving medication has been, and will continue to be, fought.

In addition to academics working in the areas of international law, development, and public health, this book will also be of interest to policy makers, state actors, and others with relevant concerns working in nongovernmental and international organizations.
Preface xi
Acknowledgements xii
Notes on Contributors xiv
Introduction: Access to Medicines and TRIPS Agreement: A Mapping of the Tradescape 1(22)
Srjvidhya Ragavan
Amaka Vanni
Part I International Norm Setting and Patent Metamorphosis: First Generation
23(122)
1 World Trade Organization: A Barrier To Global Public Health?
25(19)
Srjvidhya Ragavan
2 World Health Organization: Contributions To Access To Health And Trips Agreement Discourse
44(22)
Susan Isiko Strba
3 From Trips To Access To Medicines: What's There In Between?
66(16)
Skrgio Napolitano
4 Free Trade Agreements: Longer, Further, Deeper Impact On Pharmaceutical Patents
82(12)
Bryan Mkrcurio
5 From The Tpp To Usmca: A High-Powered Battle Over Biologies
94(17)
Burcu Kilic
6 African Union Continental Free Trade Area: Opportunities For New Regional Discourse?
111(22)
J. Jankwa Osei-Tutu
7 Us-Litigated Government-Funded Patents In Europe And Japan: A First Look
133(12)
Teo Firpo
Michael S. Mireles
Part II State Action and Access to Medicines Debate: Second Generation
145(148)
8 Brazil: Patent Barriers And Access To Medicines Through The Public Health System
147(25)
Gabriela Costa Chaves
Maria Auxiliadora Oliveira
Jorge Antonio Zepeda Bermudez
9 From Struggle To Surge: China's Trips Experience And Its Lessons For Access To Medicines
172(17)
Peter K. Yu
10 Canada: Access To Medicines In High-Income Countries
189(24)
Gaelle Groux
Jeremy De Beer
11 India: Pharmaceutical Patents And Evergreen Battle For Access To Medicines
213(22)
Anand Grover
12 South Africa's Three Decades Of Access To Medicine Discourse: Blight Or Benefit
235(17)
Caroline B. Ncube
13 Thailand: Shooting Star For Access To Medicines Through Compulsory Licensing
252(22)
Van Anh Le
14 United States: Unilateral Norm Setting Using Special 301
274(19)
Michakl Palm Edo
Part III Global Patterns and Emerging Issues: Third Generation
293(190)
15 Access To Medicines Activism: Collaboration, Conflicts, And Complementarities
295(32)
Brook K. Baker
16 Gtpi: Experiences To Overcome Ip Barriers To Increase Access To Medicines
327(17)
Felipe De Carvalho Borges Da Fonseca
Marge La Pogaca Vikira
Pedro Villardi
17 Private Sector: Right To Health Responsibilities Of Pharmaceutical Companies
344(18)
Emmanuel Kolawole Oke
18 Competition: Can Excessive Pricing Be Fixed Through Abuse Of Dominant Position?
362(17)
Shirin Syed
19 The Unique World Of Pharmaceutical Intellectual Property Rights
379(26)
Emily Michiko Morris
20 Innovation Policies: Roadblocks To Establishing Sustainable Pharmaceutical Innovation Policies
405(26)
Doris Estelle Long
21 Not Just Patents And Data F, Xclusivity: The Role Of Trademarks In Integrated Ip Strategy - Where Lies The Public Interest?
431(15)
Graham Outfield
22 Indigenous Knowledge: Bridging With Modern Medicine
446(18)
Anthony G. K. Kakooza
23 Digital Divide And Access To Medicines: The Debate
464(19)
Swaraj Paul Barooah
Part IV COVID-19 and Access to Medicines
483(14)
Lessons from COVID-19 for Medicines Access
485(12)
Amaica Vanni
Index 497
Srividhya Ragavan is a Professor of Law and Director of the India Program at Texas A&M University School of Law, Texas, United States.

Amaka Vanni is an Assistant Professor at School of Law, University of Leeds, United Kingdom.